Microbiota & Diseases

Phage: Future Treatment Direction for inflammatory bowel disease Patients

2024-04-01T16:56:35+08:00

Inflammatory bowel disease (IBD) is characterized by tissue damage resulting from uncontrolled innate and acquired immune responses. It is an autoimmune disease, including ulcerative colitis (UC), Crohn's disease (CD) and indeterminate colitis (IC). The etiology of IBD is complex, and its clinical treatment faces significant challenges, necessitating urgent exploration of new treatment methods. Emerging evidence indicates that gut microbiota and IBD interact in the occurrence and development of diseases, emphasizing the importance of restoring gut microbiota imbalance. Phages have gained attention due to their potential to their potential to act on gut microbiota, offering advantages such as high efficiency, easy access, and ability to disrupt bacterial cell structures. Consequently, research into how phages interact with bacteria and their potential as a novel treatment for IBD has become a recent hotspot. Phages regulate intestinal inflammation by activating the immune system. Previous studies have observed an increase in the abundance of Caudovirales phages in IBD patients. Latest research reveals that special combinations of bacteriophages can effectively improve the symptoms of IBD model animals. This article reviews the interaction mechanism between phages and gut microbiota as well as the related research progress in IBD. The selection of articles retrieved on PubMed based on phage and Inflammatory bowel disease.

The Microbiota & Diseases: A new platform for the cutting-edge research findings and new advances in microbiota and diseases

2024-08-27T09:25:35+08:00

Different probiotic formulations in ulcerative colitis: A bayesian network meta-analysis

2023-05-15T10:30:11+08:00

Background: To assess the efficacy and safety of probiotic formulations for the induction of remission in people with ulcerative colitis (UC). Methods: The databases of China national knowledge infrastructure (CNKI), Wanfang Data, Excerpta Medica Database (Embase), Pubmed, and Cochrane Library were searched until May 31, 2022 for randomized clinical trials (RCTs) of patients with UC. Studies had to include 5-aminosalicylate compounds (5-ASAs) as conventional therapy (CON), and 4 listed probiotic formulations used as add on therapy. Trials that recruited patients who was receiving any other treatment were excluded. A network meta-analysis was performed to access and compare different probiotic formulations. Results: 38 RCTs were included. The probiotic formulations participants received included Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Tablets (SLK), Bifid Triple Viable Capsule (BIFICO), Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules (MCA) and Bacillus licheniformis Granules (ZCS). The results of the network meta-analysis indicate that patients receiving SLK + CON (summary relative risk 1.23, 95% confidence interval 1.14 to 1.33), BIFICO + CON (1.24, 1.16 to 1.32) and MCA + CON (1.16, 1.09 to 1.24) showed a significant difference from CON in overall efficacy, SLK + CON had the highest probability of being the best treatment (surface under the cumulative ranking curve [SUCRA], 0.88). In Mayo score, SLK + CON (standardised mean difference [SMD], 1.73, 0.66 to 2.93), BIFICO + CON (1.70, 0.51 to 2.91) showed a significant difference from CON, and SLK + CON had the highest probability of being the best treatment (SUCRA, 0.83). Except that MCA + CON (relative risks [RR], 0.64, 0.41 to 0.98) showed a lower probability of adverse events compared with CON, there was no significant difference between the other pairwise comparison in terms of safety. Conclusion: Probiotic formulations confer an added benefit in inducing remission combining with 5-ASA over 5-ASA alone. SLK shows advantages in overall efficacy and Mayo score compared with the others.